Evaluating effectiveness and safety of levofloxacin in neonates and infants
Abstract
Abstract Corresponding Author Yihan Li, PharmD, BCIDP; Department of Pharmacy, NYU Langone Health, 550 First Avenue New York, NY, 10016, USA, [email protected] Funding None Conflicts of Interest None Background The increasing rate of infections caused by antimicrobial-resistant organisms in neonates and young infants has required the use of agents different than standard sepsis regimens, such as levofloxacin. There are very limited data on levofloxacin use in patients <6 months of age. As the need for levofloxacin has been increasing, we aim to evaluate the effectiveness and safety of levofloxacin in this population. Methods This single-center retrospective chart review evaluated patients <12 months of age who received at least two days of levofloxacin treatment, initiated inpatient, from 2015 to 2025. Patients <6 months of age at treatment initiation were compared to patients 6-12 months of age. The primary outcome was the incidence of treatment failure, defined as addition or escalation of antibiotics, escalation to intensive care units (ICU), or addition of vasopressors. Secondary outcomes include recurrent infection, development of resistance, and adverse effects. Results 116 patients were included, with 81 patients (69.8%) <6 months of age (median 2.3 months) and 35 patients (30.2%) 6-12 months of age (median 8.4 months). Most patients were admitted to ICUs (81.5% v. 80%) and required respiratory support at initiation (75.3% v. 65.7%), primarily invasive…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.